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Abstract
Glioblastoma Multiforme (GBM) is the most common and invasive form of malignant brain 
tumors and despite advances in surgery, radiotherapy and chemotherapy, the survival of patients 
with GBM still remains poor. Temozolomide (TMZ) is the chemotherapy drug that is most 
commonly given orally after surgical resection of these tumors. In this study, the effects of 
solvents (i.e. dichloromethane and acetonitrile) used for the fabrication of electrosprayed TMZ-
loaded poly(lactic-co-glycolic acid) (PLGA) on drug loading, loading efficiency, drug release 
kinetics, surface morphology and particle size were investigated. The results from this study 
demonstrated that by using a larger volume of a solvent with higher polarity (i.e. acetonitrile) 
which allows for a higher amount of hydrophilic TMZ to dissolve into the polymer solution, 
higher drug loading could be achieved. However, the particles fabricated with high amount of 
acetonitrile, which has a lower vapor pressure, had large pores and a smaller diameter which led to 
an initial burst release and high cumulative release at the end of the study. An optimal combination 
of the two solvents is needed to result in particles with a good amount of loading and minimal 
initial burst release. The electrosprayed microparticles were able to illicit a cytotoxic response in 
U-87 MG glioblastoma cells at a lower concentration of drug compared to the free drug. This work 
indicated that electrospraying is a promising method for the fabrication of TMZ-loaded PLGA 
microparticles for the treatment of GBM and solvent composition can be altered to control drug 
loading and release kinetics.
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Gliomas are the most common malignant brain tumors (70–80% of primary malignant brain 
tumors) and Gliobastoma Multiforme (GBM) is the most prevalent, aggressive and high-
grade form of these brain tumors (82% of malignant gliomas) [1]. Each year, around 10,000 
patients in the US are diagnosed with GBM and currently the median survival for this 
disease is around 21 months after diagnosis despite treatment with surgery, radiotherapy and 
chemotherapy [2]. Gliomas are usually treated by resection surgery and external beam 
radiation and occasionally by systemic chemotherapy or a combination of these methods [3]. 
For brain cancer, metastasis to other sites outside of the central nervous system (CNS) does 
not occur very frequently and local recurrence is the main cause of death for this disease [4]. 
Due to the infiltrative nature of these tumors, it is difficult for surgeons to completely 
remove the cancer cells without the risk of neurological deficits [5]. Thus, finding advances 
in treating the residual disease to prevent local recurrence in brain cancer patients after 
tumor resection should be an emphasis to increase the long term survival or possibly the 
complete cure of patients [6].
Systemic delivery of chemotherapy and other anti-neoplastic agents, which can inhibit or 
halt the progression of tumors, such as immunotherapy or anti-angiogenic drugs, have long 
been a method of treatment for cancer, However, many shortcomings associated with 
systemic delivery of these agents, including low local drug concentration at the targeted 
tumor site, non-target cell and organ toxicity as well as low efficacy of the delivered drug 
due to its short half-life, has emphasized the need for an alternative approach to replace this 
method of delivery. For brain malignancies, an added challenge is present for systemic 
delivery. Drugs for the treatment of these tumors also have the obstacle of having to cross 
the Blood Brain Barrier (BBB). Although some chemotherapy agents, such as the classes of 
anti-proliferation alkylating agents temozolomide (TMZ) and nitrosoureas (BCNU and 
lomustine, are able to cross the BBB to some extent and have been used clinically [7], the 
efficacy of these drugs even as a concurrent treatment to radiotherapy has been modest [8–
10]. The insufficient improvement in patient prognosis with these drugs is partly due to the 
low local drug concentrations at the targeted site due to the inadequate delivery of the drugs 
in spite of being able to cross the BBB [11, 12].
By delivering drugs locally, the drug concentration at the tumor environment can be 
maximized, non-target systemic exposure and organ toxicity can be minimized and the need 
of finding a method to cross the BBB can be avoided. Furthermore, local delivery can 
increase the efficacy of the drug as it can bypass the harsh environment and longer journey it 
has to take to reach the targeted site of interest. The development of new drugs is associated 
with high cost and difficulty. Thus, it would be beneficial if new treatment methods are 
developed to successfully deliver currently available therapeutic agents that have been 
shown to be promising in vitro, however, failed or resulted in modest outcomes when 
delivered in vivo systemically. When designing a successful drug delivery system, different 
factors such as the drug concentration, exposure time and drug administration schedule and 
sequence of delivery have to be taken into account and all these factors will differ based on 
the drug of interest. Biomaterials, such as disc, wafers and microparticles, can be optimally 
designed and utilized to accomplish this for different drugs. Compared to scaffold materials 
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such as disc and wafers, microparticles can be beneficial as it can be easily implanted to 
discrete areas by stereotaxy instead of requiring open surgery [13].
TMZ is currently the chemotherapy drug that is most commonly given after surgical 
resection of malignant glioma tumors through oral administration [2, 14] and has replaced 
BCNU as the standard therapy for GBM as it is associated with less side effects and better 
bioavailability compared to BCNU [15]. TMZ is an imidazotetrazine class DNA alkylating 
agent that functions by methylating guanine and adenine bases of DNA which results in the 
breaking of DNA double-strands and cell cycle arrest, leading to cell death [16]. Because 
TMZ is an unstable molecule with a short half-life and dose-limiting side effects [17], the 
current method of delivering TMZ alone systemically still produces modest benefits [18]. 
Thus, new strategies such as those employing biomaterials to protect the drug and enhance 
the delivery of bioactive drug to the cancer cells are much needed.
The co-polymer poly(lactic-co-glycolic acid) (PLGA) is an α-hydroxy acid-derived 
polyester that has been widely used due to its inert properties, great biocompatibility and 
versatility and thus, making it the most common material that is used for the fabrication of 
biodegradable microparticles. PLGA has been shown to have biocompatibility in the brains 
of rodents and human [19, 20]. The degradation rate of PLGA can be easily tailored from 
days to years by tuning the lactic to glycolic acid ratio, molecular weight and the end cap 
groups and thus, providing versatility in the development of microparticles to deliver 
different drugs where the release kinetics need to be tailored to fit the drug of interest. 
Because of its versatility and biosafety, PLGA has been widely used for the fabrication of 
TMZ-loaded particles for the treatment of glioblastoma [21]. There are many different 
methods of producing PLGA microparticles including emulsion solvent extraction/
evaporation [22], electrospraying [23] and microfabrication [24]. Among the different 
fabrication methods, the emulsion solvent extraction/evaporation method is the most widely 
used method for the fabrication of drug loaded microparticles as it is associated with an easy 
and low cost setup [25–27]. However, the disadvantage of this technique is that it results in a 
large loss of drug to the surrounding solutions during the fabrication process which results in 
low entrapment efficiency and drug loading [24]. To overcome this, Zhang et al. saturated 
the aqueous emulsion phase with 0.5 wt/vol % of drug (i.e. 400 mg of drug per synthesis of 
a standard batch of particles), resulting in the use of a lot of drugs which can be very costly 
[18]. Lee et al. who tried altering different parameters of fabrication of nanoparticles using 
the emulsion solvent extraction/evaporation method were not successful at obtaining high 
entrapment efficiency and drug loading and thus, concluded that the emulsion solvent 
evaporation method of fabrication of TMZ-loaded microparticles is not efficient and other 
method should be utilized to fabricate these particles [28]. Anata et al. investigated different 
emulsion solvent extraction/evaporation techniques (i.e. single and double emulsion) for the 
fabrication of TMZ/PLGA nanoparticles. They found that by using a single emulsion 
technique with TMZ saturation in the aqueous phase, they were able to increase loading 
efficiency by 90–700% and the encapsulation efficiency by 2–15-fold. However, even with 
this significant increase in loading efficiency with their method, they concluded that the 
loading efficiency of the particles still needs to be significantly improved to make it suitable 
for TMZ delivery to treat glioblastoma patients [29]. Zhang et al have shown that TMZ 
loaded PLGA microparticles synthesized by the emulsion solvent extraction/evaporation 
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have been shown to improve the survival time of animals bearing intracranial tumor [30]. 
However, to achieve this, a lot of drug was needed to fabricate the particles as the aqueous 
phase has to be saturated with the drug [30]. Thus, there is a need to find new methods to 
fabricate TMZ loaded PLGA particles to result in high drug loading and entrapment 
efficiency in order to improve the response of glioblastoma cells to these type of particles.
Thus, the objective of this study was to investigate the utilization of the electrospraying 
technique to fabricate TMZ-loaded PLGA microparticles with high drug loading and loading 
efficiency. This method requires a pump, a syringe and needle with high electric potential 
and a grounded electrode. A high voltage potential on the needle forces the polymer solution 
out of the syringe and results in the formation of a jet that breaks into monodisperse droplets 
which form the microparticles. Electrospraying is associated with many advantages 
including the ability to fabricate particles with narrow size distribution, its experimental 
setup requires low investment and it allows for scalable fabrication [31, 32]. A main reason 
for using electrospraying instead of the common emulsion solvent extraction/evaporation 
technique is that electrospraying is associated with high entrapment efficiency [32]. The 
effects of solvent used for fabrication (i.e. different volume ratio of dicholoromethane 
(DCM) and acetonitrile) of TMZ-loaded PLGA microparticles fabricated by electrospraying 
on drug loading, loading efficiency, drug release kinetics, surface morphology and particle 
size were determined. The particles were also tested on U-87 MG glioblastoma cells to 
determine their ability to induce cytotoxicity in these cells. To the best of our knowledge, 




U-87 MG glioblastoma cells were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, ATCC® HTB-14™). Dulbecco’s Modified Eagle Media (DMEM) with high 
glucose, l-glutamine and sodium pyruvate was purchased from Caisson’s Lab (Smithfield, 
UT). Fetal bovine serum (FBS) Premium Select was obtained from Atlanta Biologicals. 
Penicillin-streptomycin was obtained from GE Healthcare Life Sciences HyClone 
Laboratories (Logan, UT). Methyl tetrazolium (MTT) powder and DCM were obtained from 
Sigma-Aldrich (St. Louis, MO). Acetonitrile was purchase from VWR (Radnor, PA). 
Dimethyl sulfoxide (DMS) was obtained from Fisher Scientific (Hampton, NH). PLGA 
50:50 and (LP-779, Internal Viscosity = 0.43 dL/g, MW = 61 kDa) with an acid end group 
was obtained from Evonik Industries (Birmingham, AL). TMZ was purchased from TCI 
America (Portland, OR).
Fabrication of Electrosprayed PLGA Microparticles
PLGA microparticles loaded with TMZ were fabricated by electrospraying. Two different 
solvents, DCM and acetonitrile were investigated by themselves or in combination. The four 
different solvent combination that were fabricated are listed in Table 1 which are denoted as 
1) “TM-0” which was fabricated with 0% DCM and 100% acetonitrile, 2) “TM-25” which 
was fabricated with 25% DCM and 75% acetonitrile, 3) “TM-50” which was fabricated with 
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50% DCM and 50% acetonitrile and 4) “TM-100” which was fabricated with 100% DCM 
and 0% acetonitrile. The electrospraying setup consists of a Legato 100 Single Syringe 
Pump (KD Scientific, Holliston, MA), ES30P-5W power supply (Gamma High Voltage 
Research, Ormond Beach, FL), a copper collector plate and a glass syringe with a 21-gauge 
blunt needle tip (Hamilton, Reno, NV). A 10 mm needle-tip to copper plate distance was 
used. The pump speed of 2 mL/hr was used with a voltage of 6 kV. Briefly, for the four 
different types of microparticles, 200 mg PLGA (5 wt/vol %) and the amount of drug shown 
in the table were dissolved in a total of 4 mL of solvent. The particles were fabricated with a 
temperature and humidity range of 22–24°C and 45–50%, respectively. The amount of drug 
used for fabricating the microparticles were based on the maximum amount of TMZ that 
would dissolve into the different solvent combinations as shown in Table 1 (i.e. 20, 15, 10 
and 4 mg in 4 mL of solvent for TM-0, 25, 50 and 100, respectively). The electrosprayed 
microparticles were collected directly on the copper plate and dried under vacuum for 24 
hours to ensure complete removal of the solvent.
Drug Loading and Loading Efficiency
The amount of drug loaded into the microparticles was determined using a previous protocol 
with some modification [18]. 5 mg of microparticles were completely dissolved in 2.5 mL of 
DMSO (100%). The amount of TMZ loaded into the microparticles was determined by 
measuring the absorbance at 327 nm with a microplate reader equipped with the Magellan 
data analysis software (Tecan Infinite Pro 200, Switzerland). The drug loading and loading 
efficiency analyses were done in triplicate. The drug loading and loading efficiency were 
determined with the equations below.
Drug loading (%) =  weight of drug in sample  total weight of sample  ⋅ 100
Loading efficiency (%) =  actual amount of drug loaded  theorectical amount of drug loaded  ⋅ 100
Drug Release Kinetics
2.5 mg of microparticles were placed in 1 mL of PBS in a scintillation vial at 37°C and 
shaken at 70 rpm. At each time point (0, 1, 4, 7, 10, 14 d), the PBS was removed from the 
scintillation vials and the amount of TMZ was obtained as described above. Due to the 
instability of the TMZ in the release solution, the TMZ release in the solution was not 
measured and instead, the amount of TMZ remaining in the microparticles was used to 
calculate the cumulative release at each time point [33]. This study was conducted at n = 3.
% Cumulative Release at time X =  sum of drug released up to time X total amount of drug loaded  ⋅ 100
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Scanning Electron Microscopy (SEM) Imaging
The microparticle surface morphology was observed by Scanning Electron Microscopy 
(SEM) using a JSM-7100FA Analytical Field Emission SEM and Energy Dispersive X-Ray 
analysis System (EDS) (JEOL USA Inc., Peabody, MA). SEM images were taken using an 
electron beam with 5 kV and 6 kV. The microparticles were sputter coated with a 5 nm gold 
layer using a smart coater (JEOL) to generate electrical conduction coating on the sample 
surfaces.
Microparticle Size Determination
The diameter of the microparticles was determined from 2000× SEM images using the NIH 
Image J Software. For each image, the Feret diameter [34] of particles that the whole 
particle could be clearly identified in the images (i.e. not covered by other particles) was 
determined.
Cell Viability
An MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma 
Aldrich, St. Louis, MO) was used to analyzed the cytotoxicity of TMZ in the human U-87 
MG glioblastoma cell line as previously described for testing of microparticles [33]. The 
U-87 MG glioblastoma cells were cultured in DMEM media supplemented with 10% FBS, 
100 U/mL penicillin and 100 μg streptomycin at 37°C, 5% CO2 and 90% relative humidity. 
The cells were plated in a 96-well plate at a cell density of 1 × 104 cells/100 μL per well. 
After allowing the cells to attach overnight, the media in each well was replaced with 100 μL 
of media containing free TMZ powder, empty PLGA microparticles or TMZ-loaded PLGA 
microparticles. Wells containing only media was used as a control. After 72 hrs, an MTT 
assay was performed to determine the ability of the drugs to induce cytotoxicity in 
glioblastoma cells. Briefly, the media in each well was replaced with 100 μL of 0.5 mg/mL 
of MTT solution. After 3 hours, the MTT solution was removed and 100 μL of DMSO was 
added to each well to dissolve the formazan salts that was formed by live cells by 
metabolizing the MTT. The absorbance at 570 nm was determined with a microplate reader 
equipped with the Magellan data analysis software (Tecan Infinite Pro 200, Switzerland). 
Four wells were used for each condition (n=4) and the following equation was used to 
determine cell viability (%).
Cell viability (%) =  absorbance of test cells  absorbance of control cells  ⋅ 100
Statistical Analysis
Multiple-factor analysis of variance (ANOVA) was conducted to identify if there were any 
significant differences among groups (p < 0.05) followed by the use of Tukey’s Honestly 
Significantly Different (HSD) test to identify the specific groups that differed statistically 
significantly.
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Drug Loading and Loading Efficiency
The drug loading and loading efficiency of the four different types of microparticles are 
reported as percentages in Table 1. Particles fabricated with 0, 50, 75 and 100% DCM (i.e. 
TM-0, TM-50, TM-75 and TM-100) resulted in a drug loading of 6.60 ± 0.20, 5.25 ± 0.21, 
3.88 ± 0.21 and 1.38 ± 0.14%, respectively. The drug loading of each of the different types 
of microparticles were significantly different from one another. The loading efficiencies of 
the different microparticles were between 70–82% and were not significantly different from 
each other.
Drug Release Kinetics
The drug release kinetics of the different types of microparticles that were fabricated are 
shown in Figure 2. The microparticles that were fabricated with a higher volume of 
acetonitrile resulted in significantly higher % cumulative release (65.7 ± 8.2 and 69.3 
± 4.6% for TM-0 and TM-25, respectively) at the end of the release study (i.e. Day 14) 
compared to those fabricated with a lower amount of acetonitrile (27.4 ± 9.6% for TM-100). 
Furthermore, TM-0 and TM-25 microparticles which were fabricated with a higher volume 
of acetonitrile had a higher initial burst release (50.6 ± 1.6 and 57.9 ± 5.7%, respectively) 
compared to TM-50 and TM-100 (19.4 ± 10.1 and 0 ± 0%, respectively).
Microparticle Size and Morphology
SEM images of TM-0 and TM-25 show spherical microparticles with a porous surface of 
size reaching up to 1 micron (Figure 1A and B). TM-25 in addition to spherical particles 
shows traces of deformed biconcave disc microparticles indicating the beginning of a 
transformation process. TM-50 microparticles (Figure 1C) had a biconcave disc shape while 
further magnification show a nano-porous surface and TM-100 microparticles (Figure 1D) 
had irregular and stretched out shapes with a rough non-porous surface. Xie et al. saw 
similar morphologies for their PLGA and PCL microparticles that were fabricated by 
electrohydrodynamic atomization (EHDA). As polymer concentration decreased, the shape 
of the particles they fabricated changed from sphere to biconcave to an irregular shape [13]. 
Overall, with an increase in the amount of DCM and a decrease in the amount of acetonitrile 
used for the solvent, the size of the particles increased (2.94 ± 0.76, 3.51 ± 0.71, 4.28 ± 1.13 
and 11.50 ± 3.39 μm for TM-0, TM-25, TM-50 and TM-100, respectively). The particle size 
of TM-50 and TM-100 were significantly larger compared to TM-0 and TM-25.
Cell Viability
To test the response of glioblastoma U-87 MG cells to TMZ alone, empty PLGA 
microparticles and TMZ-loaded PLGA microparticles were determined using an MTT assay. 
TM-25 microparticles were used as an initial proof-of-concept of the bioactivity of the drug 
loaded in the electrosprayed TMZ-loaded PLGA microparticles. Empty PLGA 
microparticles did not illicit a negative response on cell viability of the glioblastoma cells 
(Figure 3A). Cells exposed to TMZ by itself (66.7 ± 7.5 and 62.3 ± 7.2%, respectively) or 
TMZ-loaded PLGA microparticles (74.1 ± 5.2 and 45.5 ± 3.0%, respectively) had a 
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significantly lower % cell viability compared to empty microparticles (119.5 ± 3.1 and 119.0 
± 7.9%, respectively) at a concentration of 500 and 1000 μM. At a drug concentration of 
1000 μM, the TMZ-loaded PLGA microparticles had a significantly lower % cell viability 
(45.5 ± 3.0%) compared to TMZ delivered by itself (62.3 ± 7.2%). For the results shown in 
Figure 3A, the drug concentration of the TMZ-loaded microparticles are the amount of drug 
that was loaded in the particles and not the actual amount that was present in the media and 
exposed to the cells. Thus, for better comparison, in Figure 3B, we compared the cell 
viability of cells exposed to TMZ by itself and TMZ-loaded microparticles based on the 
amount of TMZ that had been released into the media based on the release study. For this 
comparison, we observed that starting at 100 μM, cells exposed to TMZ-loaded 
microparticles resulted in significantly lower cell viability (74.1 ± 5.2%) compared to TMZ 
delivered by itself which had no effect on the cell viability (100.9 ± 8.9%). At a 
concentration of 200 μM, cells exposed to TMZ loaded microparticles resulted in a cell 
viability of 45.5 ± 3.0% whereas cells exposed to TMZ by itself resulted in a cell viability of 
83.5 ± 9.2%.
DISCUSSION
The emulsion solvent evaporation technique of fabricating microparticles is often used to 
fabricate PLGA microparticles due to its low cost and ease in setup. However, this method 
often results in high loss of drug to the external aqueous phase by diffusion, which leads to 
low drug loading and loading efficiency. Thus, in this work, we investigated the utilization of 
the electrospraying technique to fabricate TMZ-loaded PLGA microparticles with higher 
drug loading and loading efficiency for the treatment of glioblastoma. The effects of altering 
the solvent used for the fabrication of the microparticles on drug loading, loading efficiency 
and release kinetics and particle size and morphology were studied. The two solvents that 
were investigated were DCM and acetonitrile which have a relative polarity of 0.309 and 
0.460, respectively. Due to its hydrophilic nature [29], TMZ more readily dissolves in 
acetonitrile which is a more polar solvent. Solvent combinations with a higher volume of 
acetonitrile were able to incorporate a higher amount of drug in the electrospraying polymer/
drug/solvent solution as TMZ dissolved better in the solvent (Table 1). This resulted in 
significantly higher drug loading for microparticles fabricated with more acetonitrile 
compared to microparticles fabricated with less acetonitrile as a higher starting drug 
concentration could be used to fabricate the particles. The four different microparticles 
fabricated by electrospraying had loading efficiency of 70–82%. Zhang et al. was able to 
achieve an entrapment efficiency of around 62–85% with emulsion solvent evaporation 
method by saturating the aqueous phase and thus, using a lot of drug during the fabrication 
process [33]. Without saturation, the drug diffuses easily into the aqueous phase and the 
entrapment efficiency that was achieved by them was only around 30%. Instead of using 
only 4–20 mg of drug for fabrication with the electrospraying technique to achieve high drug 
loading and loading efficiency, an additional 400 mg of drug is needed to saturate the 
aqueous phase if the emulsion solvent evaporation method was used.
Particle porosity (i.e. pore size and amount of pores) can play a role in the release kinetics of 
drugs from particles [35]. As determined by SEM, the porosity of the microparticles 
changed with the different solvent used for fabricating the particles. The porosity of particles 
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usually increases with a decrease in solvent extraction rate [25]. In our study, we saw that an 
increase in acetonitrile volume and decrease in DCM volume resulted in higher pore size. 
Acetonitrile and DCM have a vapor pressure of 97 and 475 hPa at 20°C, respectively. A 
solvent with a higher vapor pressure exerts more pressure on the liquid phase resulting in 
higher volatility or ease of vaporization. During fabrication, the lower volatility of 
acetonitrile resulted in slower extraction of the solvent, and thus, resulted in the larger pores 
and porosity for particles with higher portions of acetonitrile. Porosity in microparticles can 
be created intentionally using porogens such as gelatin, PBS [36] or gas-forming agents or 
can be created as an artifact of the fabrication technique which can also be created such as 
the loss of absorbed oil that leaks out of particles after hardening [37] or during the freeze 
drying step at the end of the fabrication process [38]. In our study, the pores in the 
microparticles were created as an artifact of the solvent evaporation process as the particles 
travel to the copper collection plate during fabrication. Several studies have shown that 
microparticle porosity can result in initial burst release of drugs due to pore diffusion [39, 
40]. Rapid initial release of drug often occurs due to the hydration of the outer wall of the 
particles which leads to leaching of the drug [25]. Surface porosity of PLGA microparticles 
plays an essential role in determining the magnitude of this initial release due to pore 
diffusion [39]. Consistent with this, we saw that particles with large pores (TM-0 and 
TM-25) resulted in a high burst release compared to particles with small pores (TM-50) or 
no pores (TM-100) on their surface.
Surface morphology and porosity of the microparticles can also affect the rate of erosion of 
particles [41, 42]. The different microstructure of the microparticles that are created during 
the fabrication process results in a difference in the accumulation of acidic degradation 
byproduct of polyesters such as PLGA. These acidic byproducts play a role in further 
catalyzing degradation of the microparticles. The release of drugs from PLGA 
microparticles is initially dependent on diffusion through pores and channels, resulting in the 
initial burst release. As the internal porosity decreases overtime, the polymer matrix 
becomes denser. The release of the drug then starts to depend on erosion of the polymer and 
not so much on diffusion.
In addition to facilitating drug release and degradation of the particles, the pores on the 
surface of these microparticles are advantageous for our applications as they facilitate cell 
attachment [36]. Increase in interaction of the cells and particles will more likely result in 
the cancer cells uptaking the drug released from the particles.
Besides a different in porosity characteristic with change of solvent ratio, the size of the 
microparticles fabricated in this study also differed, which can also play a role in the release 
kinetics of the drug loaded. Particles that are smaller in size usually result in a high initial 
burst and/or fast release of the drug as these particles have higher surface area [43, 44]. Xie 
et al demonstrated that smaller PLGA microparticles fabricated by electrohydrodynamic 
atomization were obtained when acetonitrile was used instead of DCM [13]. We similarly 
saw that a higher ratio of acetonitrile compared to DCM resulted in smaller particle size. 
DCM and acetonitrile have a dielectric constant (indicating conductivity of the solvent) of 
9.1 and 37.5, respectively [13]. There is a positive correlation between dielectric constants 
and conductivity and thus, acetonitrile, which has a higher dielectric constant, has a higher 
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conductivity compared to DCM which has a lower dielectric constant. As seen by Xie et al, 
fabrication of particles with polymer solution with a high dielectric constant and 
conductivity results in particles with smaller size [13]. This is explained by the scaling laws 
which when rewritten, explains the inverse relationship between particle diameter (d) and 
liquid conductivity (K) as shown in the equation below [13]:
d ∝ 1K
1/6
Besides the surface porosity, the size of the microparticles also plays a role in determining 
the degradation rate of the microparticles which in turn affects release kinetics. Dunne et al 
demonstrated that there was a linear relationship between PLGA microparticles size and 
degradation rate [45]. It is more difficult for acidic byproducts to diffuse out of larger 
microparticles, thus, resulting in a higher accumulation of the autocatalytic degradation 
byproducts. The low pH in the polymer matrix results in an increase in the concentration of 
protons which can catalyze ester hydrolysis which leads to an increase in autocatalytic 
degradation of the remaining polymer matrix. The increase in degradation of the polymer 
matrix results in an increase in drug release rates for these larger particles. In the release 
study, we saw a drastic release at Day 14 for TM-50. This could have result from the change 
of release from diffusion to release through erosion of the polymer at this point.
The electrosprayed TMZ-loaded microparticles were able to better induce glioblastoma cell 
death compared to TMZ delivered by itself which indicates that the biomaterial is able to 
protect the bioactivity of the drug. The empty PLGA microparticles did not illicit a negative 
response to the cells and thus, indicating, as expected, the polymer itself is not toxic to the 
cells. MTT is often the first method used to evaluate the cytotoxic effect of drug (such as 
TMZ) loaded particles on glioblastoma cell lines [18, 33]. In the future, other methods, such 
as analysis with flow cytometry with annexin V for cell apoptosis, will be performed to 
better understand glioblastoma cell response to the optimized particles.
CONCLUSIONS
The electrospraying method of fabricating PLGA microparticles resulted in particles with 
high loading efficiency. Furthermore, this method resulted in ease in obtaining the particles 
as tedious separation of the particles from the aqueous phase is not needed as in the 
emulsion solvent evaporation method [13]. By using a larger volume of a solvent with higher 
polarity (i.e. acetonitrile) which allows for a higher amount of hydrophilic TMZ to dissolve 
into the polymer solution, higher drug loading could be achieved. However, the change in 
solvents (which have different polarity and vapor pressure) used to fabricate the 
microparticles not only changed the amount of drug loading, it also affected the surface 
morphology, porosity and size of the particles which in turn affected the release kinetics of 
the particles. Microparticles that were fabricated with high amount of acetonitrile and low 
amount of DCM resulted in a high drug loading and had large pores and a smaller diameter 
which led to an initial burst release and high cumulative release at the end of the study. 
Microparticles that were fabricated with low amount of acetonitrile and high amount of 
DCM had a low drug loading and had smaller pores or no pores and a larger diameter, 
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resulting in a more sustained release. The electrosprayed microparticles were able to illicit a 
cytotoxic response in U-87 MG glioblastoma cells at a lower concentration of drug 
compared to the free drug. In conclusion, electrospraying is a promising method to fabricate 
TMZ-loaded PLGA microparticles with high drug loading and loading efficiency that is able 
to better sustain the bioactivity of loaded drugs compared to drugs that are delivered by 
themselves. These particles can be used to delivery TMZ locally at a targeted site by 
incorporating them into a biomaterial scaffold or by redesigning them to form a colloidal gel 
which can be injected at the site of interest to form a scaffold by themselves [46]. These 
particles can be also implanted to discrete areas by stereotaxy which will not require open 
surgery [13].
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SEM images of the different microparticles: A) TM-0, B) TM-25, C) TM-50 and D) 
TM-100. The main images were taken at 2000× and the scale bar of these images represents 
10 μm. The embedded images in B) and C) were taken at 6000× and the scale bar of these 
images represents 2 μm.
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Release kinetics of the different electrosprayed particles fabricated with different solvents. 
The results are expressed as mean ± standard deviation for n = 3. Groups not connected with 
the same letter are significantly different from each other (p < 0.05).
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Cell viability of U-87 MG glioblastoma cells exposed to the TMZ only, empty PLGA 
microparticles only or TMZ loaded PLGA microparticles (i.e. TM-25) A) for 72 hours at 
different drug concentrations based on drug loaded in the TMZ microparticles and B) at 
different drug concentrations based on drug release from the TMZ microparticles at Day 4. 
The results are expressed as mean ± standard deviation for n = 4. * indicates groups that are 
significantly different (p < 0.05) from all other groups within the same drug concentration.
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Table 1.
Electrosprayed microparticles parameters and drug loading (%), loading efficiency (%) and mean diameter 
(μm) of microparticles fabricated with different parameters. The results are expressed as mean ± standard 
deviation for n = 3.
Groups Solvent ratioDCM : Acetonitrile
Amount of Drug Used for 
Fabrication (mg) Drug Loading (%) Loading Efficiency (%) Mean Diameter (μm)
TM-0 0 : 100 20 6.60 ± 0.20* 72.61 ± 2.30 2.94 ± 0.76
TM-25 25 : 75 15 5.25 ± 0.21* 75.30 ± 3.12 3.51 ± 0.71
TM-50 50 : 50 10 3.88 ± 0.21* 81.52 ± 4.49 4.28 ± 1.13*
TM-100 100 : 0 4 1.38 ± 0.14* 70.58 ± 7.40 11.50 ± 3.39*
*
indicates groups that are significantly different (p < 0.05) from all other groups.
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